Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 14/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 10/20 | 1.00 |
| ▸ | CHRNA2 | Q15822 | 4/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 4/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2495999 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| Hydrochloric Acid SCHEMBL29454390 | 0.99 | CHRNB2 (0.98) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL4727391 | 0.92 | CHRNB2 (0.86) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL2495855 | 0.92 | CHRNB2 (0.86) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL4726141 | 0.89 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL2501437 | 0.89 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL7674769 | 0.88 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL14940937 | 0.87 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL16321698 | 0.87 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 | |
| SCHEMBL7666187 | 0.87 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNA2CHRNA3CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776030-B1 | 2,5-DISUBSTITUTED-PYRIDYL NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2020-05-13 | — | — | EP | disclosed |
| US-8642612-B2 | Nicotinic desensitizers and methods of selecting, testing, and using them | POTOMAC PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642612-B2 | Nicotinic desensitizers and methods of selecting, testing, and using them | POTOMAC PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2008011484-A2 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011484-A2 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | CHRNA5, CHRNA2, CHRNA10 | CHRNB2 7/4885CHRNA4 4/4885CHRNA2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.